These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 22919537)

  • 1. Cardiovascular risk in chronic kidney disease: role of the sympathetic nervous system.
    Park J
    Cardiol Res Pract; 2012; 2012():319432. PubMed ID: 22919537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sympathetic Activation in Hypertensive Chronic Kidney Disease - A Stimulus for Cardiac Arrhythmias and Sudden Cardiac Death?
    Kiuchi MG; Ho JK; Nolde JM; Gavidia LML; Carnagarin R; Matthews VB; Schlaich MP
    Front Physiol; 2019; 10():1546. PubMed ID: 32009970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sympathetic Overactivity in Chronic Kidney Disease: Consequences and Mechanisms.
    Kaur J; Young BE; Fadel PJ
    Int J Mol Sci; 2017 Aug; 18(8):. PubMed ID: 28767097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renal denervation decreases susceptibility of the heart to ventricular fibrillation in a canine model of chronic kidney disease.
    Tang X; Shi L; Cui X; Yu Y; Qi T; Chen C; Tang X
    Exp Physiol; 2017 Nov; 102(11):1414-1423. PubMed ID: 28833735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exercise pressor response and arterial baroreflex unloading during exercise in chronic kidney disease.
    Park J; Quyyumi AA; Middlekauff HR
    J Appl Physiol (1985); 2013 Mar; 114(5):538-49. PubMed ID: 23239869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sympathetic overactivity in hypertension and cardiovascular disease.
    Manolis AJ; Poulimenos LE; Kallistratos MS; Gavras I; Gavras H
    Curr Vasc Pharmacol; 2014 Jan; 12(1):4-15. PubMed ID: 23905597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic kidney disease and risk factors responsible for sudden cardiac death: a whiff of hope?
    Kiuchi MG; Mion D
    Kidney Res Clin Pract; 2016 Mar; 35(1):3-9. PubMed ID: 27069851
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exercise pressor reflex in humans with end-stage renal disease.
    Park J; Campese VM; Middlekauff HR
    Am J Physiol Regul Integr Comp Physiol; 2008 Oct; 295(4):R1188-94. PubMed ID: 18685067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tetrahydrobiopterin lowers muscle sympathetic nerve activity and improves augmentation index in patients with chronic kidney disease.
    Park J; Liao P; Sher S; Lyles RH; Deveaux DD; Quyyumi AA
    Am J Physiol Regul Integr Comp Physiol; 2015 Feb; 308(3):R208-18. PubMed ID: 25477424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sympathetic overactivity, hypertension and cardiovascular disease: state of the art.
    Grassi G; Drager LF
    Curr Med Res Opin; 2024; 40(sup1):5-13. PubMed ID: 38597067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sympathetic nervous system and chronic renal failure.
    Boero R; Pignataro A; Ferro M; Quarello F
    Clin Exp Hypertens; 2001; 23(1-2):69-75. PubMed ID: 11270590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathogenesis of hypertension in renal failure: role of the sympathetic nervous system and renal afferents.
    Phillips JK
    Clin Exp Pharmacol Physiol; 2005; 32(5-6):415-8. PubMed ID: 15854151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role and management of sympathetic overactivity in cardiovascular and renal complications of diabetes.
    Iyngkaran P; Anavekar N; Majoni W; Thomas MC
    Diabetes Metab; 2013 Sep; 39(4):290-8. PubMed ID: 23871308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of sympathetic nervous activity in renal injury and end-stage renal disease.
    Masuo K; Lambert GW; Esler MD; Rakugi H; Ogihara T; Schlaich MP
    Hypertens Res; 2010 Jun; 33(6):521-8. PubMed ID: 20339374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiotensin converting enzyme inhibition for cardiac hypertrophy in patients with end-stage renal disease: what is the evidence?
    Wang AY; Li PK; Lui SF; Sanderson JE
    Nephrology (Carlton); 2004 Aug; 9(4):190-7. PubMed ID: 15363049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renal denervation: current implications and future perspectives.
    Xu J; Hering D; Sata Y; Walton A; Krum H; Esler MD; Schlaich MP
    Clin Sci (Lond); 2014 Jan; 126(1):41-53. PubMed ID: 24020446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular complications in renal failure.
    Rostand SG; Brunzell JD; Cannon RO; Victor RG
    J Am Soc Nephrol; 1991 Dec; 2(6):1053-62. PubMed ID: 1777585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased sympathetic nervous system activity and its therapeutic reduction in arterial hypertension, portal hypertension and heart failure.
    Esler M; Kaye D
    J Auton Nerv Syst; 1998 Oct; 72(2-3):210-9. PubMed ID: 9851571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical epidemiology of cardiovascular disease in chronic kidney disease prior to dialysis.
    Levin A
    Semin Dial; 2003; 16(2):101-5. PubMed ID: 12641872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The sympathetic nervous system in heart failure physiology, pathophysiology, and clinical implications.
    Triposkiadis F; Karayannis G; Giamouzis G; Skoularigis J; Louridas G; Butler J
    J Am Coll Cardiol; 2009 Nov; 54(19):1747-62. PubMed ID: 19874988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.